India, Sept. 5 -- US-based Edwards Lifesciences, a global leader in structural heart innovations, has announced the launch of its next-generation transcatheter heart valve platform in India, marking a significant milestone in the treatment of aortic stenosis.

This advanced therapy is designed to meet the needs of patients who are not candidates for open-heart surgery, offering a durable, minimally invasive solution that supports long-term health and quality of life.

Aortic stenosis is a progressive, degenerative condition often linked to aging, caused by calcification of the aortic valve that restricts blood flow from the heart. Once symptoms appear, nearly 50% of patients face mortality within two years without timely intervention, und...